

Mechanical Support Devices in High-Risk and/or Complex PCI



David Geffen
School of Medicine




Michael S. Lee, MD FACC, FSCAI
Associate Professor

Percutaneous LV Assist Devices


IABP




Impella



ECMO



PCI with IABP




Advantages



- Easy
- Inexpensive (\$800)
- 7F and 8F

Disadvantages

- Increases cardiac output by 0.5 L/m





ULMCA PCI With IABP



68 y.o. male with chest pain, ST-elevation in V1-V6, shock on inotropes




ULMCA PCI With IABP



68 y.o. male with chest pain, ST-elevation in V1-V6, shock on inotropes


Balloon-pump assisted Coronary Intervention Study: *BCIS-1*

Kaplan Meier 6 month mortality




IABP-Shock II Trial

Primary Study Endpoint: 30-day Mortality



PCI with Impella





Advantages

- Augment cardiac output by 3.5 L/min
- Use up to 7 days
- Does not require stable cardiac rhythm or native cardiac output/blood pressure signal for optimal function
- Unloads left ventricle

Disadvantages



- Requires 14 F catheter
- Non-pulsatile flow
- \$20,000

ULMCA PCI With Impella




85 y.o. male with CKD, polio presents with NSTEMI


ULMCA PCI With Impella



ULMCA PCI With Impella





Rotational atherectomy



Crush technique

ULMCA PCI With Impella




Final angiography

PROTECT II Trial Design

Hemodynamic support during high-risk, non-emergent PCI, N=654
Unprotected LM or last patent conduit & $EF \leq 35\%$ or 3VD & $EF \leq 30\%$

Assess myocardium at jeopardy and indicate all stenosis considered for stenting




Primary Endpoint = MAE at 30-days

3 Month Follow-up; MAE at 90-days




PROTECT II MAE Outcome

Intent to Treat (N=447)



Per Protocol (N=426)



MAE= Major Adverse Event Rate

Per Protocol= Patients that met all incl./excl. criteria.

PCI with ECMO





Advantages

- Augment cardiac output by >4.5 L/min
- Use up to several weeks
- Does not require stable cardiac rhythm or native cardiac output/blood pressure signal for optimal function
- Does not require fluoroscopy

Disadvantages


- Requires 21F and 18F catheters
- Non-pulsatile flow
- Increases afterload
- \$25,000
- Dedicated perfusionist at bedside

ULMCA PCI With ECMO




49 y.o. male with inferior ST-elevation and cardiac arrest in ED

ULMCA PCI With ECMO




**LM stent across LCX
ECMO inserted**



Compromise of LCX

ULMCA PCI With ECMO





Final angiography



Ventricular fibrillation

ULMCA PCI With ECMO



48 y.o. male with DM who presents with MI, cardiac arrest, cardiogenic shock, on ECMO


ULMCA PCI With ECMO

Derived, Filter: Filter 1




2.75 x 38 mm EES

Filter: Filter 6




Grade 3 perforation

ULMCA PCI With ECMO



LM stenting in LAO cranial




Final angiography after
covered stent

ULMCA PCI in Myocardial Infarction

Multicenter International Registry of Unprotected Left Main Coronary Artery Percutaneous Coronary Intervention With Drug-Eluting Stents in Patients With Myocardial Infarction


Michael S. Lee,^{1*} MD, Dario Sillano,² MD, Azeem Latib,³ MD, Alaide Chieffo,³ MD, Giuseppe Biondi Zoccai,² MD, Ravi Bhatia,¹ Imad Sheiban,² MD, Antonio Colombo,³ MD, and Jonathan Tobis,¹ MD

Background: Patients who present with myocardial infarction (MI) and unprotected left main coronary artery (ULMCA) disease represent an extremely high-risk subset of patients. ULMCA percutaneous coronary intervention (PCI) with drug-eluting stents (DES) in MI patients has not been extensively studied. **Methods:** In this retrospective multicenter international registry, we evaluated the clinical outcomes of 62 consecutive patients with MI who underwent ULMCA PCI with DES (23 ST-elevation MI [STEMI] and 39 non-ST-elevation MI [NSTEMI]) from 2002 to 2006. **Results:** The mean age was 70 ± 12 years. Cardiogenic shock was present in 24%. The mean EuroSCORE was 10 ± 8 . Angiographic success was achieved in all patients. Overall in-hospital major adverse cardiac event (MACE) rate was 10%, mortality was 8%, all due to cardiac deaths from cardiogenic shock, and one patient suffered a periprocedural MI. At 586 ± 431 days, 18 patients (29%) experienced MACE, 12 patients (19%) died (the mortality rate was 47% in patients with cardiogenic shock), and target vessel revascularization was performed in four patients, all of whom had distal bifurcation involvement (two patients underwent repeat PCI and two patients underwent bypass surgery). There was no additional MI. Two patients had probable stent thrombosis and one had possible stent thrombosis. Diabetes [hazard ratio (HR) 4.22, 95% confidence interval (CI) (1.07–17.36), $P = 0.04$], left ventricular ejection fraction [HR 0.94, 95% CI (0.90–0.98), $P = 0.005$], and intubation [HR 7.00, 95% CI (1.62–30.21), $P = 0.009$] were significantly associated with increased mortality. **Conclusions:** Patients with MI and ULMCA disease represent a very high-risk subgroup of patients who are critically ill. PCI with DES appears to be technically feasible, associated with acceptable long-term outcomes, and a reasonable alternative to surgical revascularization for MI patients with ULMCA disease. Randomized trials are needed to determine the ideal revascularization strategy for these patients. © 2008 Wiley-Liss, Inc.




ULMCA PCI in Myocardial Infarction

Overall Survival



STEMI vs. NSTEMI



N=62

Cardiogenic shock 24%

All in-hospital deaths from cardiogenic shock

ULMCA PCI in Myocardial Infarction



Minimum 1 hour

ULMCA PCI in Myocardial Infarction

STATE-OF-THE-ART PAPER

Unprotected Left Main Coronary Disease and ST-Segment Elevation Myocardial Infarction

“Absent a randomized trial, it is our belief that physicians and guidelines committees should recognize emergent PCI as the preferred reperfusion modality for selected patients with MI and LMCA occlusion.”

pared with CABG with acceptable short- and long-term outcomes, and is associated with a lower risk of stroke. PCI of the ULMCA should be considered as a viable alternative to CABG for selected patients with MI, including those with ULMCA occlusion and less than Thrombolysis In Myocardial Infarction flow grade 3, cardiogenic shock, persistent ventricular arrhythmias, and significant comorbidities. The higher risk of target vessel revascularization associated with ULMCA PCI compared with CABG is an acceptable tradeoff given the primary need for rapid reperfusion to enhance survival. (J Am Coll Cardiol Intv 2010;3:791-5) © 2010 by the American College of Cardiology Foundation





PRACTICE GUIDELINE

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions

Writing Committee Members*

Glenn N. Levine, MD, FACC, FAHA, *Chair*[†]
Eric R. Bates, MD, FACC, FAHA,
Vice Chair^{††}
James C. Blankenship, MD, FACC, FSCAI,
Vice Chair^{†‡}

Steven R. Bailey, MD, FACC, FSCAI[‡]
John A. Bittl, MD, FACC^{†§}
Bojan Cercek, MD, FACC, FAHA[†]
Charles E. Chambers, MD, FACC, FSCAI[‡]
Stephen G. Ellis, MD, FACC^{††}
Robert A. Guyton, MD, FACC^{†¶}
Steven M. Hollenberg, MD, FACC[†]
Umesh N. Khot, MD, FACC[†]

Richard A. Lange, MD, FACC, FAHA[§]
Laura Mauri, MD, MSc, FACC, FSCAI^{†¶}
Roxana Mehran, MD, FACC, FAHA, FSCAI[‡]
Issam D. Moussa, MD, FACC, FAHA, FSCAI[‡]
Debabrata Mukherjee, MD, FACC, FSCAI[†]
Brahmajee K. Nallamothu, MD, FACC[¶]
Henry H. Ting, MD, FACC, FAHA[†]

*Writing committee members are required to ensure themselves from writing on sections to which their specific relationships with industry and other entities may apply; see Appendix 1 for detailed information. †ACCF/AHA Representative, ‡SCAI Representative, §Joint Revascularization Section Author, ¶ACCF/AHA Task Force on Practice Guidelines Liaison, ††ACCF/AHA Task Force on Percutaneous Coronary Intervention.

ACCF/AHA Task Force Members

Alice K. Jacobs, MD, FACC, FAHA, *Chair*
Jeffrey L. Anderson, MD, FACC, FAHA,
Chair-Elect

Nancy Albert, PhD, CCNS, CCRN, FAHA
Mark A. Creager, MD, FACC, FAHA
Steven M. Erntinger, MD, FACC

Robert A. Guyton, MD, FACC
Jonathan L. Halperin, MD, FACC, FAHA
Judith S. Hochman, MD, FACC, FAHA
Frederick G. Kushner, MD, FACC, FAHA
E. Magnus Ohman, MD, FACC
William Stevenson, MD, FACC, FAHA
Clyde W. Yancy, MD, FACC, FAHA

2.2. Revascularization to Improve Survival: Recommendations

Left Main CAD Revascularization

CLASS I

1. CABG to improve survival is recommended for patients with significant ($\geq 50\%$ diameter stenosis) left main coronary artery stenosis (24–30). (*Level of Evidence: B*)

CLASS IIa


1. PCI to improve survival is reasonable as an alternative to CABG in selected stable patients with significant ($\geq 50\%$ diameter stenosis) unprotected left main CAD with: **1)** anatomic conditions associated with a low risk of PCI procedural complications and a high likelihood of good long-term outcome (e.g., a low SYNTAX score [≤ 22], ostial or trunk left main CAD); **and 2)** clinical characteristics that predict a significantly increased risk of adverse surgical outcomes (e.g., STS-predicted risk of operative mortality $\geq 5\%$) (13,17,19,23,31–48). (*Level of Evidence: B*)

2. PCI to improve survival is reasonable in patients with UA/NSTEMI when an unprotected left main coronary artery is the culprit lesion and the patient is not a candidate for CABG (13,36–39,44,45,47–49). (*Level of Evidence: B*)

3. PCI to improve survival is reasonable in patients with acute STEMI when an unprotected left main coronary artery is the culprit lesion, distal coronary flow is less than TIMI (Thrombolysis In Myocardial Infarction) grade 3, and PCI can be performed more rapidly and safely than CABG (33,50,51). (*Level of Evidence: C*)



LV Support during High-Risk PCI: *LVEF + Lesion Complexity*





John Wooden



“Failing to prepare is preparing to fail.”

